May 8, 2013
Shares plunged Wednesday after the Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen?
Updated May 8, 2013
The Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen and its shareholders?
March 27, 2013
A safer-on-the-stomach aspirin developed by Pozen has been submitted to the Food and Drug Administration for regulatory approval
Updated March 12, 2013
European patents for Pozen's combination drug technology are valid and will continue to stand, according to a decision issued by European patent authorities.
March 6, 2013
Sales of Vimovo, a pain reliever sold by partner AstraZeneca, surged in 2012, thus delivering a growing revenue stream to Chapel Hill-based Pozen. But the company still posted a $25 million dollar loss.
November 8, 2012
Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;
November 7, 2012
Results from two Phase 3 clinical trials for its proposed aspirin therapy are positive, Chapel Hill-based Pozen says.
October 2, 2012
The Chapel Hill-based pharmaceutical firm has already sold future royalty rights and milestone payments that it would have received from GlaxoSmithKline for $75 million.
August 24, 2012
After discussions with the FDA, the Chapel Hill-based drug firm says its safer form of aspirin could be ready for a drug filing in the first half of 2013.
June 26, 2012
June 21, 2012
The Chapel Hill drug developer says the FDA wants more information on PA32540, an aspirin combination drug developed to deliver the cardiovascular benefits of aspirin in a way less likely to cause stomach irritation characteristic of aspirin alone.
May 8, 2012
The migraine headache treatment developed by Pozen now has a partner for commercialization in Europe.
May 1, 2012
The Chapel Hill-based drug firm reports a loss of $8.4 million for the first quarter, up from $5.7 million a year ago. However, sales of the arthirtis drug Vimovo are growing.
April 30, 2012
During a recent meeting with the FDA to discuss its submission, the agency suggested the Chapel Hill-based company also seek approval for the drug at a lower dose
Updated March 22, 2012
The Chapel Hill-based pharmaceutical firm says its compound redcues gastric ulcers in two Phase 3 trials of patients who are taking aspirin daily. Pozen plans a new drug application in the third quarter. PLUS: Two board memebers leaving.
Diagram from Pozen presentation about PA technology
December 22, 2011
Pozen's new cardiovascular drug does not even have a name yet, but it has a manufacturer to produce it once it gets U.S. Food and Drug Administration approval.
November 28, 2011
The money strengthens Pozen's negotiating position as it seeks a partner for a drug under development and does so without diluting Pozen's shareholders, CEO John Platchetka
Updated November 28, 2011
Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline. The royalty rights were purchased by a Canadian pension plan.
Updated November 6, 2011
"Although last quarter's U.S. net sales were up from the second quarter, the $13.4 million year to date total is well below what we think Vimovo is capable of selling so AstraZeneca has work to be done to make that better," John Platchetka says.
November 3, 2011
It's been a busy earnings week, and five North Carolina firms all reported losses.